Please try another search
For the fiscal year ended 31 December 2018, Oncomed Pharmaceuticals Inc revenues increased 16% to $44.4M. Net loss before extraordinary items decreased 80% to $8.1M. Revenues reflect Collaboration revenue increase of 23% to $44.4M. Lower net loss reflects Research and Development - other decrease of 43% to $31.1M (expense), Stock-based Compensation in R&D decrease of 31% to $3.4M (expense).
Period Ending: | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
---|---|---|---|---|
Total Revenue | 10.18 | 19.52 | 6.87 | 7.85 |
Gross Profit | ||||
Operating Income | -5.02 | 5.79 | -4.89 | -5.93 |
Net Income | -4.67 | 6.12 | -3.98 | -5.57 |
Period Ending: | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
---|---|---|---|---|
Total Assets | 65.08 | 77.15 | 85.91 | 95.13 |
Total Liabilities | 16.85 | 25.43 | 41.93 | 48.8 |
Total Equity | 48.23 | 51.72 | 43.98 | 46.33 |
Period Ending: | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | -44.86 | -31.45 | -22.64 | -14.4 |
Cash From Investing Activities | 41.18 | 26.49 | 19.88 | 15.21 |
Cash From Financing Activities | 0.09 | 0.09 | 0.04 | 0.04 |
Net Change in Cash | -3.59 | -4.87 | -2.72 | 0.85 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review